{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T00:03:06Z","timestamp":1785024186018,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,12,26]],"date-time":"2015-12-26T00:00:00Z","timestamp":1451088000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s11940-015-0385-y","type":"journal-article","created":{"date-parts":[[2015,12,26]],"date-time":"2015-12-26T02:01:12Z","timestamp":1451095272000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Use of Cannabinoids for Spasticity and Pain Management in MS"],"prefix":"10.1007","volume":"18","author":[{"given":"Hardeep","family":"Chohan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariele L.","family":"Greenfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijayshree","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Graves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,26]]},"reference":[{"key":"385_CR1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.pnpbp.2015.07.001","volume":"64","author":"SPH Alexander","year":"2016","unstructured":"Alexander SPH. Therapeutic potential of cannabis-related drugs. Prog Neuro-Pharmacol Biol Psychiatry. 2016;64:157\u201366.","journal-title":"Prog Neuro-Pharmacol Biol Psychiatry"},{"issue":"3","key":"385_CR2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.5055\/jom.2009.0016","volume":"5","author":"SK Aggarwal","year":"2009","unstructured":"Aggarwal SK, Carter GT, Sullivan MD, ZumBrunnen C, Morrill R, Mayer JD. Medicinal use of cannabis in the Uniter States: historical perspectives, current trends, and future directions. J Opioid Manag. 2009;5(3):153\u201368.","journal-title":"J Opioid Manag"},{"key":"385_CR3","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/j.pain.2013.03.023","volume":"154","author":"S Maione","year":"2013","unstructured":"Maione S, Costa B, Vincenzo DM. Endocannabinoids: a unique opportunity to develop multitarget analgesics. Pain. 2013;154:S87\u201393.","journal-title":"Pain"},{"key":"385_CR4","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/346561a0","volume":"346","author":"LA Matsuda","year":"1990","unstructured":"Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346:561\u20134.","journal-title":"Nature"},{"key":"385_CR5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/365061a0","volume":"365","author":"S Munro","year":"1993","unstructured":"Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365:61\u20135.","journal-title":"Nature"},{"key":"385_CR6","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1212\/WNL.0000000000000363","volume":"82","author":"BS Koppel","year":"2014","unstructured":"Koppel BS, Brust JCM, Fife T, Bronstein J, Youssof S, Gronseth G, et al. Systematic review: efficacy and safely of medical marijuana in selected neurologic disorders. Report of the guideline development subcommittee of the American academy of neurology. Neurology. 2014;82:1556\u201363. This is a systematic review of medical marijuana from 1948- Nov 2013 which addresses treatment of symptoms of MS; and also epilepsy and movement disorders.","journal-title":"Neurology"},{"issue":"6","key":"385_CR7","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/cpt.115","volume":"97","author":"VK Vemuri","year":"2015","unstructured":"Vemuri VK, Makriyannis A. Medical chemistry of cannabinoids. Clin Pharmacol Ther. 2015;97(6):553\u20138. doi: 10.1002\/cpt.115 .","journal-title":"Clin Pharmacol Ther"},{"issue":"24","key":"385_CR8","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1001\/jama.2015.6358","volume":"313","author":"PF Whiting","year":"2015","unstructured":"Whiting PF, Wolff RF, Deshpande S, Nisio MD, Duffy S, Hernandez AV, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456\u201373. doi: 10.1001\/jama.2015.6358 . This is a 2015 meta-analysis which looked at benefits and adverse effects of cannabinoids from 28 databases, since their inception to April 2015.","journal-title":"JAMA"},{"key":"385_CR9","doi-asserted-by":"crossref","first-page":"S240","DOI":"10.1002\/acr.20543","volume":"63","author":"GA Hawker","year":"2011","unstructured":"Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res. 2011;63:S240\u201352.","journal-title":"Arthritis Care Res"},{"key":"385_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta19120","volume":"19","author":"S Ball","year":"2015","unstructured":"Ball S, Vickery J, Hobart J, Wright D, Green C, Shearer J, et al. The cannabinoid use in progressive inflammatory brain disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis. Health Technol Assess. 2015;19:1\u2013188. This is one of the largest studies in terms of patient enrollment and also has the longest duration of follow-up.","journal-title":"Health Technol Assess"},{"issue":"5","key":"385_CR11","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1191\/1352458504ms1085oa","volume":"10","author":"MA Rizzo","year":"2004","unstructured":"Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler. 2004;10(5):589\u201395.","journal-title":"Mult Scler"},{"key":"385_CR12","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/35003583","volume":"404","author":"D Baker","year":"2000","unstructured":"Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW, et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature. 2000;404:84\u20137.","journal-title":"Nature"},{"issue":"4","key":"385_CR13","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1191\/1352458504ms1048oa","volume":"10","author":"M Heinzel-Gutenbrunner","year":"2004","unstructured":"Heinzel-Gutenbrunner M, Vaney C, Jobin P, et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler. 2004;10(4):417\u201324.","journal-title":"Mult Scler"},{"issue":"4","key":"385_CR14","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1191\/1352458504ms1082oa","volume":"10","author":"P Makela","year":"2004","unstructured":"Makela P, Wade DT, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004;10(4):434\u201341.","journal-title":"Mult Scler"},{"issue":"9395","key":"385_CR15","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/S0140-6736(03)14738-1","volume":"362","author":"P Fox","year":"2003","unstructured":"Fox P, Zajicek J, Sanders H, UKMS Research Group, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003;362(9395):1517\u201326.","journal-title":"Lancet"},{"issue":"11","key":"385_CR16","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1136\/jnnp-2012-302468","volume":"83","author":"JP Zajicek","year":"2012","unstructured":"Zajicek JP, Hobart JC, Slade A, Barnes D, Mattison PG, MUSEC Research Group. Multiple sclerosis and extract of cannabis: results of the MUSEC trial. J Neurol Neurosurg Psychiatry. 2012;83(11):1125\u201332.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"385_CR17","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1468-1331.2006.01639.x","volume":"14","author":"C Collin","year":"2007","unstructured":"Collin C, Davies P, Mutiboko IK, Ratcliffe S, Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol. 2007;14(3):290\u20136.","journal-title":"Eur J Neurol"},{"issue":"5","key":"385_CR18","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1179\/016164109X12590518685660","volume":"32","author":"C Collin","year":"2010","unstructured":"Collin C, Ehler E, Waberzinek G, et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res. 2010;32(5):451\u20139.","journal-title":"Neurol Res"},{"issue":"12","key":"385_CR19","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1136\/jnnp.2005.070136","volume":"76","author":"JP Zajicek","year":"2005","unstructured":"Zajicek JP, Sanders HP, Wright DE, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry. 2005;76(12):1664\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"385_CR20","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/1352458511419700","volume":"18","author":"W Notcutt","year":"2012","unstructured":"Notcutt W, Langford R, Davies P, Ratcliffe S, Potts R. A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex\u00ae (nabiximols). Mult Scler. 2012;18:219\u201328.","journal-title":"Mult Scler"},{"key":"385_CR21","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10072-009-0136-5","volume":"30","author":"D Centonze","year":"2009","unstructured":"Centonze D, Mori F, Kock G, et al. Lack of effect of cannabis-based treatment on clinical and laboratory measures in multiple sclerosis. Neurol Sci. 2009;30:531\u20134.","journal-title":"Neurol Sci"},{"issue":"10","key":"385_CR22","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1503\/cmaj.110837","volume":"184","author":"TJ Wolfson","year":"2012","unstructured":"Wolfson TJ, Corey-Bloom J, Gamst A, Jin S, Marcotte TD, Bentley H, et al. Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. CMAJ. 2012;184(10):1143\u201350. doi: 10.1503\/cmaj.110837 .","journal-title":"CMAJ"},{"key":"385_CR23","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/clpt.1994.33","volume":"55","author":"HS Greenberg","year":"1994","unstructured":"Greenberg HS, Werness SA, Pugh JE, Andrus RO, Anderson DJ, Domino EF. Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clin Pharmacol Ther. 1994;55:324\u20138.","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"385_CR24","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1212\/WNL.58.9.1404","volume":"58","author":"J Killestein","year":"2002","unstructured":"Killestein J, Hoogervorst EL, Reif M, Kalkers NF, Van Loenen AC, Staats PG, et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology. 2002;58(9):1404\u20137.","journal-title":"Neurology"},{"key":"385_CR25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1300\/J251v07n01_04","volume":"7","author":"JT Ungerleider","year":"1987","unstructured":"Ungerleider JT, Andyrsiak T, Fairbanks L, Ellison GW, Myers LW. D-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse. 1987;7:39\u201350.","journal-title":"Adv Alcohol Subst Abuse"},{"issue":"5","key":"385_CR26","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1177\/1352458505070618","volume":"12","author":"DT Wade","year":"2006","unstructured":"Wade DT, Makela PM, House H, Bateman C, Robson P. Long-term use of cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler. 2006;12(5):639\u201345.","journal-title":"Mult Scler"},{"key":"385_CR27","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1468-1331.2010.03328.x","volume":"18","author":"A Novotna","year":"2011","unstructured":"Novotna A, Mares J, Ratcliffe S, Novakova I, Vachova M, Zapletalova O, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex((R))), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011;18:1122\u201331.","journal-title":"Eur J Neurol"},{"key":"385_CR28","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1191\/0269215503cr581oa","volume":"17","author":"DT Wade","year":"2003","unstructured":"Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil. 2003;17:21\u20139.","journal-title":"Clin Rehabil"},{"key":"385_CR29","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1212\/CPJ.0000000000000162","volume":"5","author":"TD Fife","year":"2015","unstructured":"Fife TD, Moawad H, Moschonas C, Shepard K, Hammond N. Clinical perspectives on medical marijuana (cannabis) for neurologic disorders. Neurol Clin Pract. 2015;5:344\u201351.","journal-title":"Neurol Clin Pract"},{"key":"385_CR30","doi-asserted-by":"crossref","first-page":"g2737","DOI":"10.1136\/bmj.g2737","volume":"348","author":"M Farrell","year":"2014","unstructured":"Farrell M, Buchbinder R, Hall W. Should doctors prescribe cannabinoids? BMJ. 2014;348:g2737.","journal-title":"BMJ"},{"key":"385_CR31","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1001\/jama.2015.6358","volume":"313","author":"PF Whiting","year":"2015","unstructured":"Whiting PF et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313:2456\u201373.","journal-title":"JAMA"},{"key":"385_CR32","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1001\/jama.2015.6199","volume":"313","author":"KP Hill","year":"2015","unstructured":"Hill KP. Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review. JAMA. 2015;313:2474\u201383.","journal-title":"JAMA"},{"key":"385_CR33","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1212\/01.wnl.0000176753.45410.8b","volume":"65","author":"DJ Rog","year":"2005","unstructured":"Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;65:812\u20139.","journal-title":"Neurology"},{"key":"385_CR34","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1159\/000357427","volume":"71","author":"P Flachenecker","year":"2014","unstructured":"Flachenecker P, Henze T, Zettl UK. Nabiximols (THC\/CBD oromucosal spray, Sativex\u00ae) in clinical practice\u2014results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity. Eur Neurol. 2014;71:271\u20139.","journal-title":"Eur Neurol"},{"key":"385_CR35","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/pme.12569","volume":"16","author":"D Turcotte","year":"2015","unstructured":"Turcotte D et al. Nabilone as an adjunctive to gabapentin for multiple sclerosis\u2010induced neuropathic pain: a randomized controlled trial. Pain Med. 2015;16:149\u201359.","journal-title":"Pain Med"},{"key":"385_CR36","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/cns.12358","volume":"21","author":"V Marzo Di","year":"2015","unstructured":"Di Marzo V, Centonze D. Placebo effects in a multiple sclerosis spasticity enriched clinical trial with the oromucosal cannabinoid spray (THC\/CBD): dimension and possible causes. CNS Neurosci Ther. 2015;21:215\u201321.","journal-title":"CNS Neurosci Ther"},{"key":"385_CR37","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/npp.2008.120","volume":"34","author":"RJ Ellis","year":"2008","unstructured":"Ellis RJ et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology. 2008;34:672\u201380.","journal-title":"Neuropsychopharmacology"},{"key":"385_CR38","doi-asserted-by":"crossref","first-page":"E694","DOI":"10.1503\/cmaj.091414","volume":"182","author":"MA Ware","year":"2010","unstructured":"Ware MA et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. Can Med Assoc J. 2010;182:E694\u2013701.","journal-title":"Can Med Assoc J"},{"key":"385_CR39","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1212\/WNL.0000000000000250","volume":"82","author":"V Yadav","year":"2014","unstructured":"Yadav V, Bever C, Bowen J, Bowling A, Weinstock-Guttman B, Cameron M, et al. Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis. Report of the guideline development subcommittee of the American academy of neurology. Neurology. 2014;82:1083\u201392. doi: 10.1212\/WNL.0000000000000250 . This recent paper contains guidelines on various complementary and alternative medicines in MS, including cannabinoids.","journal-title":"Neurology"},{"issue":"12","key":"385_CR40","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1016\/j.clinthera.2014.10.011","volume":"36","author":"V Yadav","year":"2014","unstructured":"Yadav V, Narayanaswami P. Complementary and alternative medical therapies in multiple sclerosis\u2014the American academy of neurology guidelines: a commentary. Clin Ther. 2014;36(12):1972\u20138. doi: 10.1016\/j.clinthera.2014.10.011 . This recent paper contains guidelines on various complementary and alternative medicines in MS, including cannabinoids.","journal-title":"Clin Ther"},{"issue":"13","key":"385_CR41","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1503\/cmaj.071178","volume":"178","author":"T Wang","year":"2008","unstructured":"Wang T, Collet JP, Shapiro S, Ware MA. Adverse effects of medical cannabinoids: a systematic review. CMAJ. 2008;178(13):1669\u201378. doi: 10.1503\/cmaj.071178 .","journal-title":"CMAJ"},{"issue":"1","key":"385_CR42","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1176\/jnp.2008.20.1.36","volume":"20","author":"P Papathanasopoulos","year":"2008","unstructured":"Papathanasopoulos P, Messinis L, Lyros E, Kastellakis A, Panagis G. Multiple sclerosis, cannabinoids, and cognition. J Neuropsychiatry Clin Neurosci. 2008;20(1):36\u201351. doi: 10.1176\/appi.neuropsych.20.1.36 .","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"1","key":"385_CR43","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/WNF.0b013e3181633497","volume":"32","author":"M Aragona","year":"2009","unstructured":"Aragona M, Onesti E, Tomassini V, Conte A, Gupta S, Gilio F, et al. Psychopathological and congnitive effects of theapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study. Clin Neuropharmacol. 2009;32(1):41\u20137. doi: 10.1097\/WNF.0B013E3181633497 .","journal-title":"Clin Neuropharmacol"},{"issue":"21","key":"385_CR44","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1212\/WNL.0000000000000446","volume":"82","author":"B Pavisian","year":"2014","unstructured":"Pavisian B, Macintosh BJ, Szilagyi G, Staines RW, O\u2019Connor P, Feinstein A. Effects of cannabis on cognition in patients with MS: a psychometric and MRI study. Neurology. 2014;82(21):1879\u201387. doi: 10.1212\/WNL.0000000000000446 .","journal-title":"Neurology"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-015-0385-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-015-0385-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-015-0385-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T19:41:49Z","timestamp":1653939709000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-015-0385-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,26]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["385"],"URL":"https:\/\/doi.org\/10.1007\/s11940-015-0385-y","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,26]]},"article-number":"1"}}